Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: What can we learn from mouse models?

Annals of the Rheumatic Diseases

Volumn 70, Issue 9, 2011, Pages 1526-1533

  Stoop, Jeroen N ^a   Robinson, John H ^a   Hilkens, Catharien M U ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; COLECALCIFEROL; COLLAGEN TYPE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 4; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; ANTIGEN SPECIFICITY; CELL THERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SAFETY; T LYMPHOCYTE; TOLEROGENIC DENDRITIC CELL; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNE TOLERANCE; MICE;

EID: 79961235625     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.151654     Document Type: Review

References (80)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. (Pubitemid 40852711)
2. Firestein GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest 2004;114:471-4. (Pubitemid 39572096)
3. Fournier C. Where do T cells stand in rheumatoid arthritis? Joint Bone Spine 2005;72:527-32. (Pubitemid 41821411)
4. Murakami M, Okuyama Y, Ogura H, et al. Local microbleeding facilitates IL-6- and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med 2011;208:103-14.
5. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: A T cell-derived proinfl ammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70. (Pubitemid 29215007)
6. Lubberts E, Joosten LA, Oppers B, et al. IL-1-independent role of IL-17 in synovial infl ammation and joint destruction during collagen-induced arthritis. J Immunol 2001;167:1004-13.
7. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-53.
8. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol 2010;32:43-53.
9. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62:2876-85.
10. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15. (Pubitemid 37409707)
11. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;Oct 7:CD007848.
12. Isaacs JD. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Expert Opin Biol Ther 2009;9:1463-75.
13. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
14. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007;46:327-34. (Pubitemid 46189796)
15. Gómez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61. (Pubitemid 46932080)
16. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.
17. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711. (Pubitemid 37174545)
18. Torres-Aguilar H, Blank M, Jara LJ, et al. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev 2010;10:8-17.
19. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008;67 (Suppl 3):iii90-6.
20. Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol 2010;29:156-83.
21. van Duivenvoorde LM, Han WG, Bakker AM, et al. Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms. J Immunol 2007;179:1506-15.
22. van Duivenvoorde LM, Louis-Plence P, Apparailly F, et al. Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factorstimulated dendritic cells. Arthritis Rheum 2004;50:3354-64.
23. Kim SH, Kim S, Evans CH, et al. Effective treatment of established murine collageninduced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001;166:3499-505. (Pubitemid 33117354)
24. Kim SH, Kim S, Oligino TJ, et al. Effective treatment of established mouse collageninduced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 2002;6:584-90. (Pubitemid 35363690)
25. Martin E, Capini C, Duggan E, et al. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum 2007;56:2255-66. (Pubitemid 47173574)
26. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001;103:407-16. (Pubitemid 32744386)
27. Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxinalpha- expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009;15:766-73.
28. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008;41:84-91.
29. Nickdel MB, Conigliaro P, Valesini G, et al. Dissecting the contribution of innate and antigen-specific pathways to the breach of self-tolerance observed in a murine model of arthritis. Ann Rheum Dis 2009;68:1059-66.
30. Xing N, L Maldonado ML, Bachman LA, et al. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 2002;297:645-52.
31. Steinbrink K, Wölfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-80. (Pubitemid 127471012)
32. Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006;116:146-55. (Pubitemid 43121799)
33. Matsue H, Yang C, Matsue K, et al. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002;169:3555-64.
34. Charbonnier LM, van Duivenvoorde LM, Apparailly F, et al. Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b+ regulatory T cells. J Immunol 2006;177:3806-13. (Pubitemid 44359914)
35. Lim DS, Kang MS, Jeong JA, et al. Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur J Immunol 2009;39:1334-43.
36. Stoop JN, Harry RA, von Delwig A. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum 2010;62:3656-65.
37. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001;107:1275-84. (Pubitemid 32494544)
38. Sarkar S, Tesmer LA, Hindnavis V, et al. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum 2007;56:89-100. (Pubitemid 46106181)
39. Cawston TE, Ellis AJ, Bigg H, et al. Interleukin-4 blocks the release of collagen fragments from bovine nasal cartilage treated with cytokines. Biochim Biophys Acta 1996;1314:226-32. (Pubitemid 26411447)
40. Joosten LA, Lubberts E, Helsen MM, et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999;1:81-91. (Pubitemid 32223676)
41. Liu Z, Xu X, Hsu HC, et al. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 2003;112:1332-41. (Pubitemid 38057687)
42. Bianco NR, Kim SH, Ruffner MA, et al. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 2009;60:380-9.
43. Fallarino F, Grohmann U, You S, et al. Tryptophan catabolism generates autoimmune-preventive regulatory T cells. Transpl Immunol 2006;17:58-60. (Pubitemid 44828801)
44. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007;178:7018-31.
45. Haase C, Ejrnaes M, Juedes AE, et al. Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood 2005;106:4225-33. (Pubitemid 41775930)
46. Kadri N, Potiron N, Ouary M, et al. Fetal calf serum-primed dendritic cells induce a strong anti-fetal calf serum immune response and diabetes protection in the nonobese diabetic mouse. Immunol Lett 2007;108:129-36. (Pubitemid 46198954)
47. Salazar L, Aravena O, Abello P, et al. Modulation of established murine collageninduced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. Ann Rheum Dis 2008;67:1235-41.
48. Salazar L, Aravena O, Contreras-Levicoy J, et al. Short-term lipopolysaccharide stimulation induces differentiation of murine bone marrow-derived dendritic cells into a tolerogenic phenotype. Eur Cytokine Netw 2007;18:78-85. (Pubitemid 47262362)
49. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6. (Pubitemid 38198821)
50. Popov I, Li M, Zheng X, et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther 2006;8:R141.
51. Jaen O, Rullé S, Bessis N, et al. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Immunology 2009;126:35-44.
52. Bertin-Maghit S, Pang D, O'Sullivan B, et al. Interleukin-1ß produced in response to islet autoantigen presentation differentiates T-helper 17 cells at the expense of regulatory T-cells: Implications for the timing of tolerizing immunotherapy. Diabetes 2011;60:248-57.
53. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003;170:1304-12. (Pubitemid 36139497)
54. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996;183:1287-92. (Pubitemid 26134270)
55. Tsark EC, Wang W, Teng YC, et al. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 2002;169:6625-33. (Pubitemid 36903517)
56. Angeli V, Randolph GJ. Infl ammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol 2006;4:217-28. (Pubitemid 46493659)
57. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 2005;17:163-9. (Pubitemid 40343103)
58. Voigtländer C, Rössner S, Cierpka E, et al. Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J Immunother 2006;29:407-15. (Pubitemid 44288953)
59. Jung YO, Min SY, Cho ML, et al. CD8alpha+ dendritic cells enhance the antigenspecific CD4+ T-cell response and accelerate development of collagen-induced arthritis. Immunol Lett 2007;111:76-83. (Pubitemid 47225129)
60. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74. (Pubitemid 39336293)
61. Reis e Sousa C, Yap G, Schulz O, et al. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. Immunity 1999;11:637-47.
62. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000;1:311-6.
63. Harry RA, Anderson AE, Isaacs JD, et al. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010;69:2042-50.
64. Hendrikx TK, Velthuis JH, Klepper M, et al. Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. Transpl Int 2009;22:884-91.
65. +T cells in mice. Transpl Immunol 2007;17:153-61.
66. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277-85. (Pubitemid 39031247)
67. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-9. (Pubitemid 46148753)
68. Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006;108:253-61. (Pubitemid 43990636)
69. Stoop JN, Woltman AM, Biesta PJ, et al. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 2007;46:699-705. (Pubitemid 47436115)
70. Morgan ME, Flierman R, van Duivenvoorde LM, et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 2005;52:2212-21. (Pubitemid 40994344)
71. Andersen KG, Butcher T, Betz AG. Specific immunosuppression with inducible Foxp3-transduced polyclonal T cells. PLoS Biol 2008;6:e276.
72. Ohata J, Miura T, Johnson TA, et al. Enhanced efficacy of regulatory T cell transfer against increasing resistance, by elevated Foxp3 expression induced in arthritic murine hosts. Arthritis Rheum 2007;56:2947-56. (Pubitemid 47502741)
73. Feitsma AL, van der Voort EI, Franken KL, et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010;62:117-25.
74. de Jong H, Berlo SE, Hombrink P, et al. Cartilage proteoglycan aggrecan epitopes induce proinfl ammatory autoreactive T-cell responses in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2010;69:255-62.
75. von Delwig A, Locke J, Robinson JH, et al. Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010;62:143-9.
76. Londei M, Savill CM, Verhoef A, et al. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci USA 1989;86:636-40.
77. van Bilsen JH, van Dongen H, Lard LR, et al. Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs proinflammatory responses in rheumatoid arthritis. Proc Natl Acad Sci USA 2004;101:17180-5.
78. Fritsch R, Eselböck D, Skriner K, et al. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol 2002;169:1068-76. (Pubitemid 34753467)
79. James EA, Moustakas AK, Bui J, et al. HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum 2010;62:2909-18.
80. Healy LJ, Collins HL, Thompson SJ. Systemic administration of tolerogenic dendritic cells ameliorates murine infl ammatory arthritis. Open Rheumatol J 2008;2:71-80.